Despite groundbreaking advancements in cell and gene therapies, the translation from the laboratory to clinical applications demands the establishment of robust and scalable manufacturing processes. A pivotal aspect of this translation in cell therapies is ensuring consistent and scalable cell expansion to prevent deviations in product quality. In the realm of gene therapies, the pursuit of scalable processes is imperative for enhancing and sustaining high viral vector productivity. As the demand for cell and gene therapies continues to grow, developing methods that are not only efficient but also capable of accommodating larger production volumes becomes paramount. These challenges necessitate real-time monitoring of Critical Process Parameters (CPPs) that impact cell growth and health. The real-time monitoring of these CPPs provides invaluable insights into the metabolic state of cell cultures, facilitating prompt adjustments to optimize production processes and enhance manufacturing robustness. This presentation by 908 Devices and Terumo Blood and Cell Technologies delves into pioneering strategies designed to address the challenges associated with cell and gene therapy manufacturing.